Chronic myeloid leukaemia

Goldman, 2003, Chronic myeloid leukaemia, N Engl J Med, 349, 1449 O’Brien, 2003, Imatinib compared with interferon and low-dose Ara-C for newly-diagnosed chronic phase chronic myeloid leukemia, N Engl J Med, 348, 994, 10.1056/NEJMoa022457 Druker, 2006, Five year follow-up of imatinib therapy for chronic-phase chronic myeloid leukemia, New Engl J Med, 355, 2408, 10.1056/NEJMoa062867 Goldman, 2007, How I treat chronic myeloid leukemia in the imatinib era, Blood, 110, 2828, 10.1182/blood-2007-04-038943 Baccarani, 2006, Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia-Net, Blood, 108, 1809, 10.1182/blood-2006-02-005686 Hughes, 2003, Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia, New Engl J Med, 349, 1421, 10.1056/NEJMoa030513 Hughes, 2006, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors – recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood, 108, 28, 10.1182/blood-2006-01-0092 1997, Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials, J Natl Cancer Inst, 89, 1616, 10.1093/jnci/89.21.1616 Gratwohl, 1998, Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation, Lancet, 352, 1087, 10.1016/S0140-6736(98)03030-X Sokal, 1984, Prognostic discrimination in ‘good risk’ chronic granulocytic leukemia, Blood, 63, 789, 10.1182/blood.V63.4.789.789